Adenosine-cannabinoid receptor interactions. Implications for striatal function

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 443-453

  Ferré, Sergi ^a   Lluís, Carme ^b   Justinova, Zuzana ^a,c   Quiroz, César ^a   Orru, Marco ^a   Navarro, Gemma ^b   Canela, Enric I ^b   Franco, Rafael ^b,d   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Basal ganglia disorders; Drug addiction; Receptor heteromers; Striatum

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR; ENDOCANNABINOID; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROTRANSMITTER;

ADDICTION; BINDING AFFINITY; BRAIN CELL; BRAIN FUNCTION; DIMERIZATION; ENZYME SYNTHESIS; HETERODIMERIZATION; HUMAN; LIGAND BINDING; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRIATE CORTEX; SYNAPTIC POTENTIAL; ANIMAL; BIOLOGICAL MODEL; CATALEPSY; CORPUS STRIATUM; DENDRITIC SPINE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SYNAPTIC TRANSMISSION;

ANIMALS; CATALEPSY; CORPUS STRIATUM; DENDRITIC SPINES; HUMANS; MODELS, BIOLOGICAL; PROTEIN MULTIMERIZATION; RECEPTOR CROSS-TALK; RECEPTOR, ADENOSINE A2A; RECEPTOR, CANNABINOID, CB1; SUBSTANCE-RELATED DISORDERS; SYNAPTIC TRANSMISSION;

EID: 77952640781     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00723.x     Document Type: Review

References (95)

1. Adermark L, Lovinger DM (2007). Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc Natl Acad Sci USA 104 : 20564 20569.
2. Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA et al 2005). Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25 : 8432 8438.
3. Ashton JC, Friberg D, Darlington CL, Smith PF (2006). Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396 : 113 116.
4. Azdad K, Gall D, Woods AS, Ledent C, Ferré S, Schiffmann SN (2009). Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34 : 972 986.
5. Brusco B, Tagliaferro PA, Saez T, Onaivi ES (2008a). Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci 1139 : 450 457.
6. Brusco B, Tagliaferro PA, Saez T, Onaivi ES (2008b). Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 62 : 944 949.
7. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR et al 2003). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278 : 46741 46749.
8. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A et al 2007). Striatal adenosine A(2A) and Cannabinoid CB(1) receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32 : 2249 2259.
9. Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L et al 2008). Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 5 : 727 733.
10. Cechova S, Venton BJ (2008). Transient adenosine efflux in the rat caudate-putamen. J Neurochem 105 : 1253 1263.
11. Chaperon F, Thiébot MH (1999). Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13 : 243 281.
12. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102 : 156 162.
13. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 : 1706 1713.
14. 2 receptors. Anal Chem 76 : 5354 5363.
15. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M et al 2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26 : 2080 2087.
16. DeLong MR, Wichmann T (2007). Circuits and circuit disorders of the basal ganglia. Arch Neurol 64 : 20 24. (Pubitemid 46072419)
17. Demuth DG, Molleman A (2006). Cannabinoid signaling. Life Sci 78 : 549 563.
18. Di Chiara G (2002). Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137 : 75 114.
19. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21 : 521 528.
20. Ferré S (1997). Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 133 : 107 120.
21. Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K (1991). Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88 : 7238 7241.
22. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997). Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 : 482 487.
23. Ferré S, Popoli P, Giménez-Llort L, Rimondini R, Müller CE, Strömberg I et al 2001). Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 7 : 235 241.
24. Ferré S, Agnati LF, Ciruela F, Lluis C, Woods AS, Fuxe K et al 2007a). Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res Rev 55 : 55 67.
25. Ferré S, Ciruela F, Woods AS, Lluis C, Franco R (2007b). Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 30 : 440 446.
26. Ferré S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F et al 2008). An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 14 : 1468 1474.
27. Ferré S, Goldberg SR, Lluis C, Franco R (2009a). Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 56 (Suppl. 1 226 234.
28. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T et al 2009b). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5 : 131 134.
29. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008). Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74 : 59 69.
30. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 : 527 552.
31. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8 : 649 652.
32. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83 : 1017 1066.
33. Gardner EL (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81 : 263 284.
34. Gerfen CR (2004). Basal ganglia. In : Paxinos G (ed.). The Rat Nervous System. Elsevier Academic Press
35. Glass M, Felder CC (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17 : 5327 5333.
36. Gomes CA, Simões PF, Canas PM, Quiroz C, Sebastião AM, Ferré S et al 2009). GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A2A receptors. J Neurochem 108 : 1208 1219.
37. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al 2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 : 10 23. (Pubitemid 43255471)
38. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF et al 2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 : 93 97.
39. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, Filizola M et al 2008). Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 27 : 2293 2304.
40. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5 : 688 695.
41. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). Endocannabinoids and synaptic function in the CNS. Neuroscientist 13 : 127 137.
42. Heimer L, Zahm DS, Alheid GF (1995). Basal ganglia. In : Paxinos G (ed.). The Rat Nervous System. Academic Press
43. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al 1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87 : 1932 1936.
44. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 : 563 583.
45. Hertz L, Zielke HR (2004). Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 27 : 735 743.
46. Jarrahian A, Watts VJ, Barker EL (2004). D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol 308 : 880 886.
47. Justinova Z, Ferré S, Redhi GH, Stroik J, Quarta D, Yasar S et al 2008). Reinforcing effects of cannabinoids, but not cocaine, are reduced by adenosine A2A receptor antagonists in squirrel monkey. Abstr Soc Neurosci 563 : 10.
48. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG (2006). Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 281 : 9066 9075.
49. Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z et al 2003). Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 : 1281 1291.
50. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67 : 1697 1704.
51. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA et al 2005). Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25 : 2874 2884.
52. Koob GF (1992). Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654 : 171 191.
53. Kreitzer AC, Malenka RC (2007). Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 : 643 647.
54. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al 1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 : 401 404.
55. Lupica CR, Riegel AC (2005). Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48 : 1105 1116.
56. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1987). Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7 : 2445 2464.
57. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I et al 2008). Antagonistic cannabinoid CB(1)/dopamine D(2) receptor interactions in striatal CB(1)/D(2) heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54 : 815 823.
58. Martín AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al 2008). Expression and function of CB(1) receptor in the rat striatum: localization and effects on D(1) and D(2) dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33 : 1667 1679.
59. Mátyás F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF (2006). Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137 : 337 361.
60. Milligan G, Smith NJ (2007). Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28 : 615 620.
61. Mitchell PB, Morris MJ (2007). Depression and anxiety with rimonabant. Lancet 370 : 1671 1672.
62. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G et al 2007). Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. Plos Biol 5 : e269.
63. Mori A, Shindou T (2003). Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61 : S44 S48.
64. Muller CE, Ferré S (2007). Blocking striatal adenosine A2A receptors: A new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2 : 1 21.
65. Navarro G, Carriba P, Gandía J, Ciruela F, Casadó V, Cortés A et al 2008). Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8 : 1088 1097.
66. Nyilas R, Dudok B, Urbán GM, Mackie K, Watanabe M, Cravatt BF et al 2008). Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J Neurosci 28 : 1058 1063.
67. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY et al 2005). Astrocytic purinergic signaling coordinates synaptic networks. Science 310 : 113 116.
68. Pickel VM, Chan J, Kash TL, Rodríguez JJ, MacKie K (2004). Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 : 101 112.
69. Pickel VM, Chan J, Kearn CS, Mackie K (2006). Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 495 : 299 313.
70. Piomelli D (2003). The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4 : 873 884.
71. Pistis M, Muntoni AL, Pillolla G, Gessa GL (2002). Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 15 : 1795 1802.
72. Quarta D, Ferré S, Solinas M, You ZB, Hockemeyer J, Popoli P et al 2004a). Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 88 : 1151 1158.
73. Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F et al 2004b). Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem 91 : 873 880.
74. Quiroz C, Luján R, Uchigashima M, Simoes AP, Lerner TN, Borycz J et al 2009). Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 9 : 1321 1344.
75. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R et al 2007). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104 : 654 659.
76. van Rijn RM, Whistler JL (2009). The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 66 : 777 784.
77. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001). Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 21 : 109 116.
78. Robbins TW, Everitt BJ (1996). Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6 : 228 236.
79. Robertson GS, Jian M (1995). D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience 64 : 1019 1034.
80. Rodriguez JJ, Mackie K, Pickel VM (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate-putamen nucleus. J Neurosci 21 : 823 833.
81. Ronesi J, Gerdeman GL, Lovinger DM (2004). Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24 : 1673 1679.
82. Rosin DL, Hettinger BD, Lee A, Linden J (2003). Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61 : S12 SS8.
83. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007). Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83 : 277 292.
84. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22 : 565 572.
85. Shindou T, Arbuthnott GW, Wickens JR (2008). Actions of adenosine A2A receptors on synaptic connections of spiny projection neurons in the neostriatal inhibitory network. J Neurophysiol 99 : 1884 1889.
86. So CH, Verma V, Alijaniaram M, Cheng R, Rashid AJ, O'Dowd BF et al 2009). Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 75 : 843 854.
87. Solinas M, Yasar S, Goldberg SR (2007). Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 56 : 393 405.
88. Soria G, Castañé A, Ledent C, Parmentier M, Maldonado R, Valverde O (2006). The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31 : 978 987.
89. Surmeier DJ, Song WJ, Yan Z (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16 : 6579 6591.
90. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P (2004). DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44 : 269 296.
91. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276 : 2048 2050.
92. Tebano MT, Martire A, Chiodi V, Pepponi R, Ferrante A, Domenici MR et al 2009). Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J Neurochem 110 : 1921 1930.
93. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007). Subcellular arrangement of molecules for 2-arachidonoyl-glycerol- mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27 : 3663 3676.
94. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH (2005). Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314 : 329 337.
95. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96 : 5780 5785. (Pubitemid 29234695)